<DOC>
	<DOCNO>NCT00942825</DOCNO>
	<brief_summary>This randomize , open-label , multicenter , phase II study compare triplet combination CBP501 , pemetrexed cisplatin pemetrexed/cisplatin administer patient locally advance ( stage IIIB malignant pleural effusion pericardial effusion ) metastatic ( stage IV ) non-squamous NSCLC consecutive i.v . infusion accord once-every-3-weeks schedule . The protocol evaluate full-dose cisplatin pemetrexed without CBP501 . Patients randomize 1:1 ratio pemetrexed , cisplatin CBP501 ( Arm A ) pemetrexed cisplatin ( Arm B ) . Randomization stratify accord whether patient eligible bevacizumab therapy . The combination cisplatin/pemetrexed come recognize new standard care patient untreated , unresectable malignant pleural mesothelioma ( MPM ) untreated NSCLC non-squamous cell histology . Preclinical clinical finding support protocol : - CBP501 exhibit interesting preclinical activity various lung cancer cell line . - Synergism document CBP501/cisplatin preclinical study lung cancer cell line . - The dose-limiting toxicity ( DLT ) CBP501 rapid onset allergic reaction , suggest preclinical toxicology . Other toxicity quite limited . No evidence potentiation either CBP501 cisplatin toxicity find combination phase I trial , toxicity combination , primarily relate cisplatin , manageable . It expect CBP501 pemetrexed display non-overlapping toxicity profile combination , give hematological toxicity gastrointestinal toxicity principal toxicity type latter . - Given acceptable safety cisplatin/ pemetrexed combination , anticipated addition CBP501 combination evaluate without excessive risk phase II program . - The phase I study CBP501 combination pemetrexed/cisplatin ( phase I part mesothelioma program ) show DLTs evidence enhancement toxicity triplet combination . The RD CBP501 25 mg/m² , cisplatin 75 mg/m² pemetrexed 500 mg/m² currently use phase II study first line mesothelioma patient . - Hints activity observe phase I study CBP501 cisplatin . - No pharmacokinetics ( PK ) interaction document cisplatin CBP501 .</brief_summary>
	<brief_title>Triplet Combination First Line Treatment Non Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Pleural Effusion</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Signed informed consent obtain prior initiation studyspecific procedure Histologically cytologically confirm diagnosis nonsquamous non small cell lung cancer ( NSCLC ) , amenable radical resection , stage IIIB pleural pericardial effusion stage IV , receive previous chemotherapy systemic treatment At least one unidimensionally measurable lesion accord Response Evaluation Criteria Solid Tumors ( RECIST ) Male female patient age least 18 year ECOG Performance Status ( PS ) : 01 Life expectancy &gt; 3 month Prior local radiotherapy allow complete ≥ 3 week prior first dose study medication Concomitant palliative radiotherapy exist bone lesion pain control allow Prior surgery allow perform least 4 week prior first dose study medication patient fully recover Adequate organ function , include follow : Bone marrow : white blood cell ( WBC ) count &gt; = 4 x 109/L , absolute neutrophil count ( ANC ) &gt; = 1.5 x 109/L , platelet count &gt; = 100 x 109/L , hemoglobin &gt; = 9 g/dL Hepatic : Bilirubin ≤ 1.5 x upper limit normal ( ULN ) , aspartate transaminase ( AST/SGOT ) alanine transaminase ( ALT/SGPT ) ≤ 2.5 x ULN ( ≤ 5 x ULN liver metastasis present ) , INR ≤ 1.5 x ULN , albumin &gt; = 3.0 g/dL Renal : Serum creatinine ≤ 1.5 mg/dL creatinine clearance &gt; = 45 mL/min ( calculate accord Cockroft Gault formula ) Female patient childbearing potential must negative pregnancy test use least one form contraception approve Investigator 4 week prior study 4 month last dose study drug . For purpose study , childbearing potential define : `` All female patient unless postmenopausal least one year surgically sterile '' Male patient must use form barrier contraception approve Investigator study 4 month last dose study drug Ability cooperate treatment followup Radiation therapy 30 % bone marrow prior entry study Histology pure bronchioloalveolar carcinoma neuroendocrine feature tumor sample Previous treatment chemotherapy , new biological therapy ( small molecule , antibody ) , immunotherapy Absence measurable lesion An ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , symptomatic poorly control cardiac arrhythmia , uncontrolled thrombotic hemorrhagic disorder , serious uncontrolled medical disorder opinion Investigator Any previous history another malignancy within 5 year study entry ( cure basal cell carcinoma skin cure insitu carcinoma cervix ) Presence significant central nervous system ( CNS ) psychiatric disorder ( ) would hamper patient 's compliance Evidence peripheral neuropathy &gt; grade 1 accord NCICTCAE Version 3 Treatment investigational agent , participation another clinical trial within 28 day prior study entry Pregnant breastfeeding patient patient childbearing potential use adequate contraception Known HIV , HBV , HCV infection Presence symptomatic brain metastasis . Patients brain metastasis must : Have stable neurologic status follow local therapy ( surgery radiation ) least 2 week completion definitive therapy . Be without neurologic dysfunction would confound evaluation neurologic AEs Inability unwillingness take folic acid , vitamin B12 corticosteroid Inability interrupt aspirin nonsteroidal antiinflammatory agent , aspirin dose ≤ 1.3 gram per day , 5day period ( 8day period longacting agent , piroxicam ) Significant weight loss ( &gt; = 10 % body weight precede 6 week ) Presence clinically significant ( physical exam ) third space fluid collection , e.g. , ascites pleural effusion control drainage procedure prior study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>NSCL</keyword>
	<keyword>non-squamous non small cell lung cancer</keyword>
	<keyword>Lung Cancer</keyword>
	<keyword>Lung</keyword>
	<keyword>non-squamous</keyword>
	<keyword>metastatic</keyword>
	<keyword>pleural effusion</keyword>
	<keyword>Stage IIIb</keyword>
	<keyword>Stage IV</keyword>
	<keyword>NSCLC</keyword>
</DOC>